{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germline+Mutation",
    "query": {
      "condition": "Germline Mutation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 76,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germline+Mutation&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T17:09:41.953Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05072483",
      "title": "Natural History Study of CADASIL",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Disease",
        "Arterial Stiffness",
        "Germline Mutation in the NOTCH 3 Gene",
        "Pathogenesis of CADASIL",
        "Clinical Phenotype of CADASIL"
      ],
      "interventions": [
        {
          "name": "MRI",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 155,
      "start_date": "2022-04-18",
      "completion_date": "2041-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05072483"
    },
    {
      "nct_id": "NCT03286842",
      "title": "To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HER2-ve Metastatic Breast Cancer",
        "Germline BRCA1/2 Mutations",
        "Somatic BRCA1/2 Mutations"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 256,
      "start_date": "2018-01-17",
      "completion_date": "2021-10-08",
      "has_results": true,
      "last_update_posted_date": "2023-01-17",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 2,
      "location_summary": "Towson, Maryland • Jackson, Mississippi",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03286842"
    },
    {
      "nct_id": "NCT02154672",
      "title": "Prostate Cancer Screening in Men With Germline BRCA2 Mutations",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "90 Years",
        "sex": "MALE",
        "summary": "30 Years to 90 Years · Male only"
      },
      "enrollment_count": 1,
      "start_date": "2014-05",
      "completion_date": "2019-11-01",
      "has_results": true,
      "last_update_posted_date": "2021-02-09",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02154672"
    },
    {
      "nct_id": "NCT07218575",
      "title": "Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Cowden's Disease",
        "Cowden's Syndrome",
        "Lhermitte-Duclos Disease",
        "Cerebellum Dysplastic Gangliocytoma",
        "Bannayan Zonana Syndrome",
        "Myhre Riley Smith Syndrome",
        "Riley Smith Syndrome",
        "PTEN Hamartoma Tumor Syndrome",
        "Bannayan Riley Ruvalcaba Syndrome"
      ],
      "interventions": [
        {
          "name": "Everolimus blinded oral capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "5 Years to 45 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-09-01",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Boston, Massachusetts • Cleveland, Ohio",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07218575"
    },
    {
      "nct_id": "NCT02000622",
      "title": "Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer Metastatic",
        "BRCA 1 Gene Mutation",
        "BRCA 2 Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Physician's choice chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 302,
      "start_date": "2014-03-27",
      "completion_date": "2025-12-23",
      "has_results": true,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 42,
      "location_summary": "San Diego, California • Santa Rosa, California • Whittier, California + 35 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000622"
    },
    {
      "nct_id": "NCT05141708",
      "title": "Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Breast Cancer",
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2021-12-17",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-02-16",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05141708"
    },
    {
      "nct_id": "NCT05721326",
      "title": "Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Genetic Predisposition to Disease",
        "Breast Cancer Female",
        "Ovarian Cancer",
        "Hereditary Breast and Ovarian Cancer",
        "Hereditary Cancer Syndrome",
        "Hereditary Diseases",
        "Gene Mutation-Related Cancer"
      ],
      "interventions": [
        {
          "name": "Sequential EHR Communications",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 100 Years · Female only"
      },
      "enrollment_count": 1283,
      "start_date": "2023-05-01",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05721326"
    },
    {
      "nct_id": "NCT02184195",
      "title": "Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Germline BRCA1/2 Mutations and",
        "Metastatic Adenocarcinoma of the Pancreas"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 154,
      "start_date": "2014-12-16",
      "completion_date": "2023-01-27",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 20,
      "location_summary": "Gilbert, Arizona • Orange, California • Stanford, California + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184195"
    },
    {
      "nct_id": "NCT03830229",
      "title": "Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mesothelioma",
        "Families"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2019-03-13",
      "completion_date": "2027-07-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03830229"
    },
    {
      "nct_id": "NCT03140670",
      "title": "Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "RUCAPARIB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2017-09-05",
      "completion_date": "2023-08-07",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-06-25T17:09:41.953Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03140670"
    }
  ]
}